Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2025	Mar. 10, 2026	Jun. 30, 2025
Document Information [Line Items]
Entity Central Index Key	0002022416
Entity Registrant Name	Silexion Therapeutics Corp
Document Type	10-K/A
Document Period End Date	Dec. 31, 2025
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Amendment Flag	true
Entity Current Reporting Status	Yes
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	12 Abba Hillel Road
Entity Address, City or Town	Ramat-Gan
Entity Address, Postal Zip Code	5250606
Entity Address, Country	IL
City Area Code	972
Local Phone Number	3 756-4999
Document Transition Report	false
Entity File Number	001-39157
Entity Tax Identification Number	00-0000000
Entity Common Stock, Shares Outstanding		3,330,785
Entity Public Float			$ 0
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Annual Report	true
Amendment Description	EXPLANATORY NOTE This Amendment No. 1 on Form 10-K/A (this “Amendment”) to the Annual Report on Form 10-K of Silexion Therapeutics Corp (the “Company”, “we”, “us” or “our”) for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 17, 2026 (the “Original 10-K”), is being filed solely to amend and restate Part II “Item 9A. Controls and Procedures” to correct typographical errors whereby the date as of which the Company’s management evaluated the effectiveness of our internal control over financial reporting is stated as December 31, 2024 whereas that evaluation was actually carried out as of December 31, 2025. Those typographical errors are corrected in this Amendment. This Amendment contains only the cover page, this explanatory note, the complete text of Item 9A, the exhibit list, a signature page and the certifications of the Company’s principal executive and financial and accounting officers under the Sarbanes Oxley Act of 2002, as amended. Other than as expressly set forth herein (including updated versions of Exhibits 3.5 and 10.5.2 listed in the exhibit index, which reflect updated versions of matters included in the Original 10-K that have been approved by our shareholders since the filing of the Original 10-K), this Amendment does not, and does not purport to, amend, update or restate the information in the Original 10-K or reflect any events that have occurred after the Original 10-K was filed. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original 10-K was filed. This Amendment should be read together with the Original 10-K and the Company’s other filings with the SEC.
Ordinary Shares [Member]
Document Information [Line Items]
Trading Symbol	SLXN
Security Exchange Name	NASDAQ
Title of 12(b) Security	Ordinary shares, par value $0.0135 per share
Warrants exercisable for ordinary shares [Member]
Document Information [Line Items]
Trading Symbol	SLXNW
Security Exchange Name	NASDAQ
Title of 12(b) Security	Warrants exercisable for ordinary shares at an exercise price of $1,552.50 per share

Silexion Therapeutics Corp 10-K/A